Severity of Disease and Outcomes in Vaccinated and Non Vaccinated Covid patients in District Muzaffarabad AJK

2021 ◽  
Vol 15 (11) ◽  
pp. 3074-3075
Author(s):  
Munazza Nazir ◽  
Sohail Khan Raja ◽  
Noman Kareem Qureshi ◽  
Syed Sajid Ali Bukhari ◽  
Farooq Ahmed ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Viral Vector ◽  
Vector Vaccine ◽  
Severity Of Disease ◽  
Viral Vector Vaccine

Aim: Covid infection after first and second dose of vaccination was assessed in comparison to unvaccinated SARS-CoV-2 infection patients. Methodology: Patients were divided into two groups: those who had not got any immunizations and those who had received vaccines that were prescribed. Individuals who have taken second dose of either the mRNA vaccine or the viral vector vaccine and have a positive COVID-19 within 14 days of receiving their second dose are deemed fully immunised. Results: Among 180 patients, the males were 75% and 25% was females. In our study, 16.7% (30/180) patients still suffered from COVID-19 despite of the fact that they were vaccinated, but the ratio of immune patients was greater i.e. 83.3% (150/180).The severity of the symptoms in vaccinated patients was much lesser and in some cases almost nil. 144/180 (80%) patients did not suffer from any severe symptoms after vaccination. 33/180 (18.3%) patients showed moderate symptoms while 3/180 (1.7%) showed severe symptoms. In the analysis of severity of symptoms of non vaccinated patients, 70% (126/180) showed severe symptoms, 25% (45/180) showed moderate and 5% (9/180) patients showed low symptoms. Conclusion: People without vaccination have more severe symptoms whereas COVID patients with vaccination had a reduced mortality rate and milder symptoms. Keywords: SARS-COV-2, vaccination, without vaccination

Hatchery Vaccination Quality Control of Herpesvirus of Turkey-Infectious Bursal Disease HVT-IBD Viral Vector Vaccine Application by Specific qPCR

2012 ◽  
Vol 11 (9) ◽  
pp. 570-576 ◽  
Author(s):  
Stephane Lemiere ◽  
Francisco Perozo ◽  
Blandine de Saint-Vis ◽  
Jennifer Diasparra ◽  
Arnaud Carlotti ◽  
...  
Keyword(s):  
Quality Control ◽  
Viral Vector ◽  
Infectious Bursal Disease ◽  
Vector Vaccine ◽  
Bursal Disease ◽  
Viral Vector Vaccine

scholarly journals Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19

2021 ◽  
Vol 8 ◽  
Author(s):  
Rajashri Bezbaruah ◽  
Pobitra Borah ◽  
Bibhuti Bhushan Kakoti ◽  
Nizar A. Al-Shar’I ◽  
Balakumar Chandrasekaran ◽  
...  
Keyword(s):  
Viral Vectors ◽  
Ebola Virus ◽  
Vaccine Development ◽  
Viral Vector ◽  
World Health ◽  
Prolonged Incubation ◽  
Vaccine Candidates ◽  
Vector Vaccine ◽  
Dna And Rna ◽  
Viral Vector Vaccine

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, arose at the end of 2019 as a zoonotic virus, which is the causative agent of the novel coronavirus outbreak COVID-19. Without any clear indications of abatement, the disease has become a major healthcare threat across the globe, owing to prolonged incubation period, high prevalence, and absence of existing drugs or vaccines. Development of COVID-19 vaccine is being considered as the most efficient strategy to curtail the ongoing pandemic. Following publication of genetic sequence of SARS-CoV-2, globally extensive research and development work has been in progress to develop a vaccine against the disease. The use of genetic engineering, recombinant technologies, and other computational tools has led to the expansion of several promising vaccine candidates. The range of technology platforms being evaluated, including virus-like particles, peptides, nucleic acid (DNA and RNA), recombinant proteins, inactivated virus, live attenuated viruses, and viral vectors (replicating and non-replicating) approaches, are striking features of the vaccine development strategies. Viral vectors, the next-generation vaccine platforms, provide a convenient method for delivering vaccine antigens into the host cell to induce antigenic proteins which can be tailored to arouse an assortment of immune responses, as evident from the success of smallpox vaccine and Ervebo vaccine against Ebola virus. As per the World Health Organization, till January 22, 2021, 14 viral vector vaccine candidates are under clinical development including 10 nonreplicating and four replicating types. Moreover, another 39 candidates based on viral vector platform are under preclinical evaluation. This review will outline the current developmental landscape and discuss issues that remain critical to the success or failure of viral vector vaccine candidates against COVID-19.

Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster

2018 ◽  
Vol 63 (2) ◽  
pp. 368-374
Author(s):  
Guanbo Wang ◽  
Longzheng Yu ◽  
Artemis Efstratiou ◽  
Paul Franck Adjou Moumouni ◽  
Mingming Liu ◽  
...  
Keyword(s):  
Protective Effect ◽  
Plasmid Dna ◽  
Viral Vector ◽  
Recombinant Adenovirus ◽  
Vaccination Strategy ◽  
Challenge Infection ◽  
Babesia Microti ◽  
Post Challenge ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

AbstractIn the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, againstBabesia microtiinfection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection withB.microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection againstB.microtichallenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting againstB.microtiinfection.

scholarly journals Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers

2015 ◽  
Vol 46 (1) ◽  
pp. 114-118 ◽  
Author(s):  
Kaissar Tabynov ◽  
Sholpan Ryskeldinova ◽  
Zhailaubay Kydyrbayev ◽  
Abylai Sansyzbay
Keyword(s):  
Brucella Abortus ◽  
Viral Vector ◽  
Booster Vaccination ◽  
Positive Control ◽  
Control Group ◽  
The Novel ◽  
Subcutaneous Route ◽  
Control Groups ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

ABSTRACT: The present study provides the first information about the safety of a new influenza viral vector vaccine expressing the Brucella ribosomal protein L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with B. abortus S19 (n=10) or B. abortus RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Clinical studies, thermometry, assessment of local reactogenicity and observation of abortion showed that the vector vaccine via the conjunctival or subcutaneous route was completely safe for pregnant heifers compared to the commercial vaccines B. abortus S19 or B. abortus RB51. The only single adverse event was the formation of infiltration at the site of subcutaneous injection; this reaction was not observed for the conjunctival route.

scholarly journals Cutting Edge: Mucosal Application of a Lyophilized Viral Vector Vaccine Confers Systemic and Protective Immunity toward Intracellular Pathogens

2009 ◽  
Vol 182 (5) ◽  
pp. 2573-2577 ◽  
Author(s):  
Wolfgang Kastenmuller ◽  
Georg Gasteiger ◽  
Leon Stross ◽  
Dirk H. Busch ◽  
Ingo Drexler
Keyword(s):  
Protective Immunity ◽  
Viral Vector ◽  
Cutting Edge ◽  
Intracellular Pathogens ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Tanveer Alam Khan ◽  
Navneet Sidhu ◽  
Livia Khan ◽  
Seema Sen ◽  
Nishat Hussain ◽  
...  
Keyword(s):  
Viral Vector ◽  
Vector Vaccine ◽  
Immune Mediated ◽  
Viral Vector Vaccine

scholarly journals Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1780
Author(s):  
Onur Kaynarcalidan ◽  
Sara Moreno Mascaraque ◽  
Ingo Drexler
Keyword(s):  
Vaccinia Virus ◽  
Viral Vector ◽  
Vaccination Campaign ◽  
Smallpox Vaccination ◽  
Vaccine Candidates ◽  
Vector Vaccine ◽  
Host Restriction ◽  
Genetic Manipulations ◽  
Modified Vaccinia Virus Ankara ◽  
Viral Vector Vaccine

Various vaccinia virus (VACV) strains were applied during the smallpox vaccination campaign to eradicate the variola virus worldwide. After the eradication of smallpox, VACV gained popularity as a viral vector thanks to increasing innovations in genetic engineering and vaccine technology. Some VACV strains have been extensively used to develop vaccine candidates against various diseases. Modified vaccinia virus Ankara (MVA) is a VACV vaccine strain that offers several advantages for the development of recombinant vaccine candidates. In addition to various host-restriction genes, MVA lacks several immunomodulatory genes of which some have proven to be quite efficient in skewing the immune response in an unfavorable way to control infection in the host. Studies to manipulate these genes aim to optimize the immunogenicity and safety of MVA-based viral vector vaccine candidates. Here we summarize the history and further work with VACV as a vaccine and present in detail the genetic manipulations within the MVA genome to improve its immunogenicity and safety as a viral vector vaccine.

scholarly journals The viral vector vaccine VSV-GP boosts immune response upon repeated applications

Retrovirology ◽  
2012 ◽  
Vol 9 (Suppl 2) ◽  
pp. P301
Author(s):  
R Tober ◽  
Z Banki ◽  
A Ejaz ◽  
A Muik ◽  
L Egerer ◽  
...  
Keyword(s):  
Immune Response ◽  
Viral Vector ◽  
Vector Vaccine ◽  
Repeated Applications ◽  
Viral Vector Vaccine
Sign in / Sign up

Export Citation Format

Share Document